ClinicalTrials.Veeva

Menu

Effects of Hyaluronic Acid Complex and Dexamethasone on Pain, Swelling, and Trismus After Mandibular Third Molar Surgery

C

Cyprus Health and Social Sciences University

Status

Completed

Conditions

Postoperative Morbidity

Treatments

Drug: Hyaluronic Acid Complex
Device: Absorbable Hemostatic Gelatin Sponge (SPONGOSTAN™ Dental)
Drug: Dexamethasone

Study type

Interventional

Funder types

Other

Identifiers

NCT07853196
KSTU//2026/009

Details and patient eligibility

About

This study aimed to comparatively evaluate the effects of a hyaluronic acid complex and dexamethasone on postoperative pain, swelling, and trismus following mandibular third molar surgery, compared with a control group. Participants were evaluated in three groups: a hyaluronic acid complex group, a dexamethasone group, and a control group. Postoperative pain, facial swelling, and limitation of mouth opening were assessed during the postoperative follow-up period to compare postoperative outcomes among the groups.

Enrollment

45 patients

Sex

All

Ages

18 to 35 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Age between 18 and 35 years.
  • No systemic disease.
  • No regular medication use.
  • Non-smoker.
  • Not pregnant or lactating.
  • Presence of an asymptomatic partially impacted mandibular third molar indicated for prophylactic surgical extraction.

Exclusion criteria

  • Presence of acute pericoronitis.
  • Presence of an abscess or acute odontogenic infection.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

45 participants in 3 patient groups

Control Group
Active Comparator group
Description:
Following mandibular third molar extraction, SPONGOSTAN™ Dental absorbable hemostatic gelatin sponge (MS0005; 1 × 1 × 1 cm; Ethicon, Johnson \& Johnson) was placed into the extraction socket. No hyaluronic acid complex or dexamethasone was administered. The surgical site was primarily closed with 3/0 silk sutures, which were removed on postoperative day 7.
Treatment:
Device: Absorbable Hemostatic Gelatin Sponge (SPONGOSTAN™ Dental)
Hyaluronic Acid Complex Group
Experimental group
Description:
Following mandibular third molar extraction, 0.2 mL of Monovisc® (22 mg/mL cross-linked high-molecular-weight sodium hyaluronate; Anika Therapeutics, Inc., Bedford, MA, USA), corresponding to 4.4 mg of sodium hyaluronate, was applied directly into the extraction socket. SPONGOSTAN™ Dental was subsequently placed to enhance retention within the socket. The surgical site was primarily closed with 3/0 silk sutures, which were removed on postoperative day 7.
Treatment:
Device: Absorbable Hemostatic Gelatin Sponge (SPONGOSTAN™ Dental)
Drug: Hyaluronic Acid Complex
Dexamethasone Group
Experimental group
Description:
Following mandibular third molar extraction, 1.5 mL of DEKORT® 8 mg/2 mL I.M./I.V. solution for injection (DEVA Holding A.Ş., Türkiye), corresponding to 6 mg of dexamethasone, was absorbed into SPONGOSTAN™ Dental and placed into the extraction socket. The surgical site was primarily closed with 3/0 silk sutures, which were removed on postoperative day 7.
Treatment:
Drug: Dexamethasone
Device: Absorbable Hemostatic Gelatin Sponge (SPONGOSTAN™ Dental)

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems